Dr. Thomas Stinchcombe on Targeted Therapies in Squamous Cell Lung Cancer
Thomas Stinchcombe, MD, discusses the complicated nature of squamous cell lung cancer. Stinchcombe says that there has been a recent boom in targeted therapies for non-squamous cell lung cancer, though not as much research in squamous cell lung cancer due to its multitude of mutations.
Thomas Stinchcombe, MD, assistant professor in the Division of Hematology and Oncology, codirector of the multidisciplinary thoracic oncology program, University of North Carolina Lineberger Cancer Center, discusses the complicated nature of squamous cell lung cancer. Stinchcombe says that there has been a recent boom in targeted therapies for non-squamous cell lung cancer, though not as much research in squamous cell lung cancer due to its multitude of mutations.
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
November 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
